Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Pipeline Review, H2 2016

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Plasminogen (Plasmin or PLG or EC 3.4.21.7) Overview 7
Therapeutics Development 8
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Products under Development by Stage of Development 8
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Products under Development by Therapy Area 9
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Products under Development by Indication 10
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Products under Development by Companies 13
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Companies Involved in Therapeutics Development 22
Bayer AG 22
Bharat Biotech International Limited 23
F. Hoffmann-La Roche Ltd. 24
Grifols, S.A. 25
Hyundai Pharmaceutical Co., Ltd. 26
Kedrion S.p.A. 27
Nostrum Pharmaceuticals, LLC 28
Omeros Corporation 29
ProMetic Life Sciences Inc. 30
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Drug Profiles 31
alteplase - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
OMS-616 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
plasminogen (human) - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
plasminogen (human) - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
plasminogen (recombinant) - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Recombinant Prourokinase - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecule to Inhibit Plasminogen for Rare Bleeding Disorder - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
SMRX-11 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
TAL-0500018 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
THR-100 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
TMS-007 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
tranexamic acid - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
TTS-01 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Dormant Projects 47
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Discontinued Products 49
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Featured News & Press Releases 50
Jun 13, 2016: ProMetic plasminogen granted Fast Track designation by the US FDA 50
May 11, 2016: Positive response in kidney and urinary tract to ProMetic plasminogen treatment in a plasminogen deficient patient under an expanded access protocol in the USA 50
May 10, 2016: Major new global study identifies a safer treatment of acute stroke 51
May 03, 2016: Prometic announces successful treatment of a plasminogen deficient patient under an expanded access (compassionate use) protocol in the USA 52
Feb 18, 2016: Clot-busting therapy reduces mortality in deadliest form of stroke 53
Dec 07, 2015: ProMetic's plasminogen demonstrates rapid therapeutic response in second clinical case 55
Nov 04, 2015: Prometic'S Plasminogen Drug Successfully Used to Treat Plasminogen Deficient Infant in Critical Condition 56
Aug 10, 2015: Prometic Successfully Completes First Dosing In Plasminogen Deficient Patients 56
Aug 04, 2015: European Commission Grants Orphan Drug Designation to ProMetic's Plasma-Derived Plasminogen Drug 57
Jul 23, 2015: MHRA review confirms benefit/risk profile of Alteplase - the only licensed clot buster for acute ischaemic stroke 58
Oct 28, 2014: ProMetic's Plasminogen IND and Clinical Program Cleared by FDA 58
Aug 22, 2014: MHRA To Review Ischemic Stroke Drug 59
Feb 13, 2014: CSIR Developed Clot Specific Streptokinase Enters into Phase-2 Human Clinical Trials 59
Jun 25, 2013: Kedrion Announces Plasminogen clinical study now started on drug for treatment of ligneous conjunctivitis 61
Feb 28, 2013: Mitsubishi Tanabe Pharma And Kyowa Hakko Kirin Receive Japanese Approval For Time-Window Extension Of Thrombolytic Agents GRTPA And Activacin 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Mechanism of Action, H2 2016 17
Number of Products by Stage and Route of Administration, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 21
Pipeline by Bayer AG, H2 2016 22
Pipeline by Bharat Biotech International Limited, H2 2016 23
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 24
Pipeline by Grifols, S.A., H2 2016 25
Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 26
Pipeline by Kedrion S.p.A., H2 2016 27
Pipeline by Nostrum Pharmaceuticals, LLC, H2 2016 28
Pipeline by Omeros Corporation, H2 2016 29
Pipeline by ProMetic Life Sciences Inc., H2 2016 30
Dormant Projects, H2 2016 47
Dormant Projects (Contd..1), H2 2016 48
Discontinued Products, H2 2016 49 

To request a free sample copy of this report, please complete the form below.

Enter captcha code*

We never share your personal data. Privacy policy